The UGT2B17 gene deletion polymorphism and risk of prostate cancer: A case-control study in Caucasians

Cancer Detection and Prevention

Volumn 32, Issue 3, 2008, Pages 186-187

  Gallagher, Carla J ^a   Kadlubar, Fred F ^b   Muscat, Joshua E ^a   Ambrosone, Christine B ^a   Lang, Nicholas P ^b,c,d   Lazarus, Philip ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B17; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; CAUCASIAN; CONTROL GROUP; DIGITAL RECTAL EXAMINATION; GENE DELETION; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; LETTER; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT;

EID: 52949099116     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2008.08.005     Document Type: Letter

References (3)

1. Gallagher C.J., Kadlubar F.F., Muscat J.E., Ambrosone C.B., Lang N.P., and Lazarus P. The UGT2B17 gene deletion polymorphism and risk of prostate cancer: a case-control study in Caucasians. Cancer Detect Prev 31 (2007) 310-315
2. Thompson I.M., Ankerst D.P., Chi C., Lucia M.S., Goodman P.J., Crowley J.J., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (2005) 66-70
3. Olsson M., Lindstrom S., Haggkvist B., Adami H.O., Balter K., Stattin P., et al. The UGT2B17 gene deletion is not associated with prostate cancer risk. Prostate 68 (2008) 571-575